Moderna vaccine's effectiveness bodes well for Oxford/AstraZeneca jab
by Nicola Davis and Jessica Elgot from Science | The Guardian on (#5AEXQ)
Phase 3 success rate of 95% for US firm's treatment is promising for UK vaccine trial
Hopes are rising for the Covid jab being developed by Oxford University, after Moderna became the second company to reveal impressive results from its vaccine trials.
Interim results from phase 3 clinical trials of the Covid vaccine from US company Moderna has revealed it to be almost 95% effective at preventing the disease. The news followed an announcement last week from Germany-based Pfizer and BioNTech that their vaccine was more than 90% effective.
Continue reading...